The missionary pioneer : or, A brief memoir of the life, labours, and death of John Stewart, (man of colour,) founder, under God, of the mission among the Wyandotts, at Upper Sandusky, Ohio, /

Photocopy. Ann Arbor, Mich. : University Microfilms International, 1980.--21 cm.

Teghekagir gortsadir handznazhoghovoy Azgayin sahmanadrutʻian nerkayatsʻeal hatean ěndhanur zhoghovoy Azgayin Erespʻokhnutʻian i 20 september amsoy 1863.

Mode of access: Internet.

The collected works of Dugald Stewart.

v. 1. Dissertation: exhibiting the progress of metaphysical, ethical, and political philosophy, since the revival of letters in Europe. 1854.--v. 2-4. Elements of the philosophy of the human mind ... To which is prefixed introduction and part first of the Outlines of moral philosophy. 1854.--v. 5. Philosophical essays. 1855.--v. 6-7. The philosophy of the active and moral powers of man ... To which is prefixed part second of the Outlines of moral philosophy. 1855.--v. 8-9. Lectures on political economy ... To which is prefixed part third of the Outlines of moral philosophy. 1855.56.--v. 10. Biographical memoirs of Adam Smith, William Robertson, Thomas Reid. To which is prefixed a Memoir of Dugald Stewart, with selections from his correspondence. By J. Veitch. 1858.--v. 11. Translations of the passages in foreign languages contained in the collected works of Dugald Stewart. With general index. 1860.

Pereseleniia krest'ian Riazanskoi gubernii

Mode of access: Internet.

Using clinical indicators in a quality improvement programme targeting cardiac care

Rationale. The Brisbane Cardiac Consortium, a quality improvement collaboration of clinicians from three hospitals and five divisions of general practice, developed and reported clinical indicators as measures of the quality of care received by patients with acute coronary syndromes or congestive heart failure. Development of indicators. An expert panel derived indicators that measured gaps between evidence and practice. Data collected from hospital records and general practice heart-check forms were used to calculate process and outcome indicators for each condition. Our indicators were reliable (kappa scores 0.7-1.0) and widely accepted by clinicians as having face validity. Independent review of indicator-failed, in-hospital cases revealed that, for 27 of 28 process indicators, clinically legitimate reasons for withholding specific interventions were found in

Tumour susceptibility to innate and adaptive immunotherapy changes during tumour maturation

Immunotherapy of tumours using T cells expanded in vitro has met with mixed clinical success suggesting that a greater understanding of tumour/T-cell interaction is required. We used a HPV16E7 oncoprotein-based mouse tumour model to study this further. In this study, we demonstrate that a HPV16E7 tumour passes through at least three stages of immune susceptibility over time. At the earliest time point, infusion of intravenous immune cells fails to control tumour growth although the same cells given subcutaneously at the tumour site are effective. In a second stage, the tumour becomes resistant to subcutaneous infusion of cells but is now susceptible to both adjuvant activated and HPV16E7-specific immune cells transferred intravenously. In the last phase, the tumour is susceptible to intravenous transfer of HPV16E7-specific cells, but not adjuvant-activated immune cells. The requirement for IFN-gamma and perforin also changes with each stage of tumour development. Our data suggest that effective adoptive T-cell therapy of tumour will need to be matched with the stage of tumour development.

ISCOMATRIX (TM) adjuvant: An adjuvant suitable for use in anticancer vaccines

Human Papillomavirus type 16 (HPV16) E6 and E7 oncoproteins are associated with cervical cancer development and progression and can therefore be used as target antigens for cancer immunotherapy. In this study we evaluated the immunogenicity in mice, of different vaccine formulations using recombinant HPV16 derived E6E7 or E7GST fusion proteins. When co-administered with ISCOMATRIX(TM) adjuvant, these E6E7 proteins consistently induced E7 specific CTL, in vivo tumor protection, antibody and DTH responses. ISCOMATRIX(TM) adjuvant has been developed for use in the formulation of novel human vaccines and has been evaluated for safety and toxicity in human trials. A formulation containing aluminum hydroxide (Al(OH)(3)) gave a lesser degree of E7 specific antibody, and no local E7 specific CTL response but similar DTH and tumor protection. These findings demonstrate the potential of ISCOMATRIX(TM) adjuvant to stimulate both cellular and humoral immune responses to endogenously processed target antigens, and hence is the preferred adjuvant when CTL responses are desirable. (C) 2004 Elsevier Ltd. All rights reserved.